TABLE 13.
Medication classes and corresponding share of preventability of DRAs related to treatment safety.
| Medication classes repeatedly involved in DRAs related to treatment safety | DRAs related to treatment safety (No.) | Preventable DRAs related to treatment safety (No.) | Share (%) |
|---|---|---|---|
| Anti-inflammatory and antirheumatic products | 13 | 12 | 92 |
| Psycholeptics | 5 | 4 | 80 |
| Drugs used in diabetes | 8 | 6 | 75 |
| Antihypertensives | 2 | 1 | 50 |
| Cardiac therapy | 8 | 4 | 50 |
| Calcium channel blockers | 3 | 1 | 33 |
| Psychoanaleptics | 5 | 1 | 20 |
| Analgesics | 11 | 2 | 18 |
| Antithrombotic agents | 65 | 10 | 15 |
| Diuretics | 28 | 4 | 14 |
| Beta blocking agents | 14 | 2 | 14 |
| Agents acting on the renin-angiotensin system | 13 | 1 | 8 |
DRA, Drug-related hospital admission.
Note: Medication classes involved only once in DRAs and medication classes that were not involved in preventable DRAs related to treatment safety were excluded.